Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $8.36 USD
Change Today -0.05 / -0.59%
Volume 95.9K
SRNE On Other Exchanges
As of 5:10 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

sorrento therapeutics inc (SRNE) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/23/15 - $26.80
52 Week Low
11/28/14 - $3.72
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

sorrento therapeutics inc (SRNE) Related Businessweek News

No Related Businessweek News Found

sorrento therapeutics inc (SRNE) Details

Sorrento Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. The company primary therapeutic focus is oncology, including the treatment of chronic cancer pain, as well as developing therapeutic products for other indications, such as immunology and infectious diseases. Its lead product, Cynviloq, is polymeric, albumin-free nanoparticle paclitaxel formulation, approved and marketed in South Korea for metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), and ovarian cancer under the trade name Genexol-PM. Cynviloq has also completed Phase I, Phase II, and Phase III clinical trials, and post-marketing surveillance studies in MBC, NSCLC, ovarian, pancreatic, and bladder cancer. The company is also developing resiniferatoxin, a non-opiate, ultra potent, and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease. In addition, the company’s preclinical human therapeutic monoclonal antibodies include human anti- PD-L1 and anti-PD-1 checkpoint inhibitors; antibody drug conjugates; and bispecific antibodies, as well as Chimeric Antigen Receptor Tumor-attacking Neukoplast for adoptive cellular immunotherapies. It has a collaboration agreement with Conkwest Incorporated to generate and develop products for adoptive immunocellular therapy utilizing Neukoplast cells and chimeric antigen receptors; and NantWorks, Inc. to develop anti-cancer immunotherapies. Sorrento Therapeutics, Inc. was founded in 2006 and is headquartered in San Diego, California.

66 Employees
Last Reported Date: 03/16/15
Founded in 2006

sorrento therapeutics inc (SRNE) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $582.5K
Executive Vice President of Clinical and Regu...
Total Annual Compensation: $337.5K
Total Annual Compensation: $341.2K
Compensation as of Fiscal Year 2014.

sorrento therapeutics inc (SRNE) Key Developments

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

On 11/09/2015, Sorrento Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Sorrento Therapeutics, Inc. Appoints Jeffrey Su as Executive Vice President and Chief Operating Officer

Sorrento Therapeutics, Inc. announced the addition of Jeffrey Su, Ph.D., as Executive Vice President and Chief Operating Officer. Dr. Su will be responsible for all manufacturing operations at Sorrento, including the analytical and process development laboratories, the newly constructed cGMP manufacturing facility, and all required quality systems. Prior to joining Sorrento, Dr. Su was Chief Scientific and Development Officer at Cytovance Biologics Inc.

Sorrento Therapeutics, Inc. Presents at BIO-Europe 2015, Nov-02-2015

Sorrento Therapeutics, Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRNE:US $8.36 USD -0.05

SRNE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SRNE.
View Industry Companies

Industry Analysis


Industry Average

Valuation SRNE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 77.0x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 44.8x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SORRENTO THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at